Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immune Medicine operation

Investors are watching Adaptive Biotechnologies (ADPT) after forecasts pointed to a reduced quarterly loss of $0.13 per share and 12.6% revenue growth for the June 2026 quarter, alongside its track record of beating earnings estimates. See our latest analysis for Adaptive Biotechnologies. At a share price of $22.31, Adaptive Biotechnologies has seen strong recent momentum, including a 29.48% 1 month share price return and a 57.78% 3 month share price return, while the 1 year total shareholder...

Adaptive Biotechnologies stock has delivered very strong total returns over the past three years, while its valuation signals are pulling in different directions, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting upside and market based multiples pointing to a richer price. Shareholders have seen a 185.3% total return over three years, which puts extra focus on whether the current price still leaves room for further upside. Expectations for future revenue growth in...

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earlier this week, Adaptive Biotechnologies was upgraded to a Zacks Rank #2 (Buy) following upward revisions to its earnings estimates and expectations for a smaller quarterly loss alongside higher revenue for the June 2026 quarter. This shift in analyst expectations suggests confidence that the company’s underlying business trends are improving, supported by a recent pattern of earnings estimate beats. Now we’ll examine how this upward revision in earnings expectations may influence...

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.